Akebia Therapeutics Inc (AKBA)
1.865
-0.06
(-2.86%)
USD |
NASDAQ |
Nov 14, 16:00
1.865
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Research and Development Expense (Quarterly): 8.487M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 8.487M |
| June 30, 2024 | 7.647M |
| March 31, 2024 | 9.731M |
| December 31, 2023 | 9.865M |
| September 30, 2023 | 13.33M |
| June 30, 2023 | 20.20M |
| March 31, 2023 | 19.69M |
| December 31, 2022 | 32.10M |
| September 30, 2022 | 28.03M |
| June 30, 2022 | 26.03M |
| March 31, 2022 | 43.83M |
| December 31, 2021 | 29.56M |
| September 30, 2021 | 40.47M |
| June 30, 2021 | 37.21M |
| March 31, 2021 | 40.61M |
| December 31, 2020 | 37.58M |
| September 30, 2020 | 46.86M |
| June 30, 2020 | 52.82M |
| March 31, 2020 | 81.23M |
| December 31, 2019 | 80.41M |
| September 30, 2019 | 74.51M |
| June 30, 2019 | 85.69M |
| March 31, 2019 | 82.35M |
| December 31, 2018 | 87.05M |
| Date | Value |
|---|---|
| September 30, 2018 | 70.63M |
| June 30, 2018 | 71.92M |
| March 31, 2018 | 61.40M |
| December 31, 2017 | 68.38M |
| September 30, 2017 | 58.71M |
| June 30, 2017 | 43.75M |
| March 31, 2017 | 60.05M |
| December 31, 2016 | 33.44M |
| September 30, 2016 | 31.24M |
| June 30, 2016 | 30.88M |
| March 31, 2016 | 20.24M |
| December 31, 2015 | 14.24M |
| September 30, 2015 | 15.60M |
| June 30, 2015 | 6.505M |
| March 31, 2015 | 6.664M |
| December 31, 2014 | 4.933M |
| September 30, 2014 | 6.648M |
| June 30, 2014 | 5.525M |
| March 31, 2014 | 6.158M |
| December 31, 2013 | 1.311M |
| September 30, 2013 | 3.24M |
| June 30, 2013 | 2.453M |
| March 31, 2013 | 1.898M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.647M
Minimum
Jun 2024
81.23M
Maximum
Mar 2020
33.28M
Average
30.83M
Median
Research and Development Expense (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 59.34M |
| Bioventus Inc | 3.808M |
| Eli Lilly and Co | 2.734B |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 4.672M |